In:
Medicinus, Universitas Pelita Harapan, Vol. 7, No. 1 ( 2019-02-15), p. 2-
Abstract:
〈 p 〉 〈 em 〉 Acinetobacter baumanii 〈 /em 〉 ( 〈 em 〉 A. baumanii 〈 /em 〉 ) has arisen as the most important cause of nosocomial infection, typically in severely ill patients with many comorbidities and medical supportive devices. Tigecycline is a therapeutic option for treating this infection because of its potential ability against wide spectrum of bacterias, including multi-drug resistance 〈 em 〉 A. baumannii 〈 /em 〉 (MDRAB). 〈 em 〉 〈 /em 〉 Our study determine the in vitro susceptibility of tigecycline against 〈 em 〉 A. baumanii 〈 /em 〉 isolates and the emergence of MDRAB. The frequency of isolates that were not inhibited at MIC ≤ 0.5 µg/ml was 50.46%, at MIC = 1µg/ml was 2.38%, and at MIC = 2 µg/ml was 19.07%. The susceptibility rate of tigecycline against 〈 em 〉 A. baumanii 〈 /em 〉 was 68.27% in 2015, 79.58% in 2016, and 67.87% in 2017. In vitro result demonstrated that tigecycline had good value of MIC against 〈 em 〉 A. baumanii 〈 /em 〉 at the range of 0.5 to 2 µg/ml 〈 em 〉 . 〈 /em 〉 〈 em 〉 〈 /em 〉 〈 /p 〉
Type of Medium:
Online Resource
ISSN:
2622-6995
,
1978-3094
DOI:
10.19166/med.v7i1.1436
Language:
Unknown
Publisher:
Universitas Pelita Harapan
Publication Date:
2019
Permalink